Status:
COMPLETED
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Lead Sponsor:
Astellas Pharma Europe B.V.
Collaborating Sponsors:
Veeda Clinical Research
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Tremodi is an observational, non-interventional, prospective, open-label, non-comparative study that will collect real life data of a treatment with Depo-Eligard® in 3 different administrations in mal...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients having been prescribed Depo-Eligard® 7.5 mg - 22.5 mg - 45 mg in accordance with the terms of the marketing authorization.
Exclusion
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT01793077
Start Date
December 1 2011
End Date
December 1 2013
Last Update
January 13 2014
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Site: 5
Antwerp, Antwerp, Belgium, 2018
2
Site: 8
Antwerp, Antwerp, Belgium, 2018
3
Site: 9
Antwerp, Antwerp, Belgium, 2018
4
Site: 14
Antwerp, Antwerp, Belgium, 2020